Risk factors for potential drug–drug interactions in patients with myasthenia gravis-Reference-Cited by-同舟云学术

Risk factors for potential drug–drug interactions in patients with myasthenia gravis

Published:2021-07-07 Issue:12 Volume:43 Page:1023-1030
ISSN:0161-6412
Container-title:Neurological Research
language:en
Short-container-title:Neurological Research

Author:

Aleksić Dejan Z.¹,Milosavljević Miloš N.²^ORCID,Stefanović Srđan M.³,Bukonjić Andriana³,Milosavljević Jovana Z.⁴^ORCID,Janković Slobodan M.²^ORCID,Božović Ivo⁵,Perić Stojan⁵⁶,Lavrnić Dragana⁵⁶

Affiliation:

1. Department of Neurology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

2. Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

3. Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

4. Department of Anatomy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

5. Neurology Clinic, Clinical Center of Serbia, Belgrade, Belgrade, Serbia

6. Department of Neurology, School of Medicine, University of Belgrade, Belgrade, Serbia

Funder

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja

Publisher

Informa UK Limited

Subject

Clinical Neurology,Neurology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/01616412.2021.1948767

Reference38 articles.

1. International consensus guidance for management of myasthenia gravis

2. Epidemiological Study of Adult-Onset Myasthenia Gravis in the Area of Belgrade (Serbia) in the Period 19792008

3. Survival and mortality of adult-onset myasthenia gravis in the population of Belgrade, Serbia

4. Treatment of Myasthenia Gravis

5. Myasthenia gravis and specific immunotherapy: monoclonal antibodies

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and Risk Factors of Potential Drug-Drug Interactions in the In-Patient Medical Wards: A Hospital-Based Cross-Sectional Study;International Journal of Life Science and Pharma Research;2022-10-21